Vivid Vision Perimetry. Digital endpoints for GA, AMD, and Glaucoma clinical trials.

get 6.8x more precision using

TARGETED MICROPERIMETRY

for

Retina & Glaucoma

in your next trial

Vivid Vision Perimetry, high precision home visual field testing for clinical trials.

&

introducing

VIVID VISION PERIMETRY

...offering

AFFORDABLE, MOBILE

automated perimetry!

Slide background

Vivid Vision is also an advanced vison training system for

AMBLYOPIA, STRABISMUS, & CI

Discover a world
with depth perception!

3D VISION

by training your

DIGITAL
ENDPOINTS

VVP is being used as a targeted microperimetry endpoint in clinical trials for GA, AMD, and glaucoma.

VISUAL
FIELD

Learn more about how Vivid Vision Perimetry is used to measure visual fields.

VT FOR
PATIENTS

Find a Vivid Vision Provider
who can provide vision training.

EYEBAB
VT

To take your patients to the next level, EYEBAB offers a suite of dozens of vision activities.

Pioneering digital solutions for vision care

Used by more than 100,000 patients, in 50+ countries, since 2014.

Proven Superior to In-Clinic Microperimetry

Our pilot study demonstrates that at-home natural fixation VR-based vision testing matches the accuracy of in-clinic microperimetry while providing greater precision.

6.8x
More Precision Than SAP
2x
Better Fixation Stability
100%
At-Home Testing
Research by Leading Experts
Study sponsored by Regeneron and conducted by Dr. Karl Csaky at the Retina Foundation of the Southwest, a premier research institution.
Industry Partnerships
Used by the largest ophthalmic pharma companies, demonstrating industry confidence in Vivid Vision Perimetry as a functional vision endpoint for clinical trials.
Clinical Trial Ready
Targeted microperimetry is already validated for use as an endpoint in phase I and II clinical trials for geographic atrophy, AMD, and glaucoma therapeutics.

What Leading Researchers Are Saying

"

Vivid Vision's visual field test is extremely promising to use as an endpoint in clinical trials. I am personally excited about the potential it has for helping pharmaceutical companies bring their new therapeutics to market.

- Eleonora Lad, MD, PhD
Vice Chair of Clinical Research, Ophthalmology
Duke University Medical Center
"

At the RFSW, we were proud to be the first site to evaluate VVP tests in patients with Geographic Atrophy. For our GA patients, VVP wasn't just a novel tool, it became the test of choice.

- Karl Csaky, MD, PhD
CEO, CMO
Retina Foundation of the Southwest

We are committed to quality

Our system goes through scientific testing and rigorous quality management procedures